50 closest statements
by meaning · ranked by similarity · 100 per pageMeaning search returns the 50 nearest statements, then applies your filters.
“Our mission is to create life-changing T cell therapies for patients with cancer and autoimmune disorders.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0490% match
“Our mission is to bring off-the-shelf cellular immunotherapies with disease-transforming potential initially to patients with autoimmune diseases and cancer.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2680% match
“Our mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1080% match
“Our mission is to create therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-04-1678% match
“Our mission is to deliver advanced therapies to improve the lives of patients and families battling autoimmune and inflammatory diseases.”In use 2025 – now·1 sighting·SEC Form 10-K, filed 2025-04-1577% match
“Our mission is to liberate patients from autoimmune diseases through the curative potential of cell therapy.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-2677% match
“Our mission is to transform patients’ lives by providing them with life-changing medicines which build on scientific breakthroughs in immunology.”In use 2025 – now·1 sighting·SEC Form 20-F, filed 2025-03-2076% match
“Our mission is to develop therapeutics that restore healthy immune regulation for patients with severe autoimmune and inflammatory diseases.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1075% match
“Our mission is to bring hope with life-changing therapies to patients and families that are affected by rare and niche allergic and immunological diseases.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-03-2275% match
“Our mission is to revolutionize the treatment of solid tumors with a single dose of engineered TCR T-cells and as a result to address cancers with high unmet needs.”In use 2025 – now·1 sighting·SEC Form 10-K, filed 2025-03-2474% match
“Our mission is to improve patient outcomes in the areas of neurodegenerative and oncological diseases by developing safe and effective cellular therapies that leverage the power of a patient’s immune system.”In use 2025 – now·1 sighting·SEC Form 10-K, filed 2025-10-0874% match
“Our mission is to build a breakthrough oncology company creating neoantigen-based therapies that significantly improve the lives of patients.”In use 2018 – now·1 sighting·SEC Form 424B4, filed 2018-06-2874% match
“Our mission is to create, develop, manufacture, and deliver cell and gene therapies to transform the lives of people impacted by life-threatening diseases.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-1874% match
“Our mission is to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte, or TIL, cell therapies for patients with solid tumor cancers.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2473% match
“Our mission is to develop therapies that empower the immune system to cure neurodegeneration and other diseases.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-02-2773% match
“Our mission is to develop next-generation, potentially curative cell therapies for people with cancer.”In use 2025 – now·1 sighting·SEC Form 10-K, filed 2025-03-1272% match
“Our mission is to target cancer and transform lives through the development of innovative cancer treatments.”In use 2005 – now·1 sighting·SEC Form 10-K, filed 2005-03-1671% match
“Our mission is to make a meaningful impact on the lives of patients with cancer and high unmet medical needs by delivering novel, PRAME-directed immunotherapies that provide tangible clinical benefits.”In use 2026 – now·1 sighting·SEC Form 20-F, filed 2026-03-0571% match
“Our mission is to build a leading oncology company that creates novel and transformative treatments for a wide range of oncology indications for which there are significant unmet medical needs.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-0771% match
“Our mission is to improve the lives of patients by developing novel therapeutics to treat some of the most devastating types of cancer.”In use 2026 – now·1 sighting·SEC Form 10-K/A, filed 2026-06-0271% match
“Our mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of therapeutic agents.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-3071% match
“Our mission is to discover, develop and commercialize novel and transformative therapies that improve the lives of patients with serious diseases.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-02-2271% match
“Lyell’s mission is to fully realize the curative potential of next-generation CAR T-cell therapies and meaningfully improve outcomes for patients with cancer.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1271% match
“Our mission is to become a global leader in developing better and safer radioimmunotherapy and antibody-based oncology therapies addressing clear unmet medical needs and, as such, have a transformational impact on the lives of patients.”In use 2025 – now·1 sighting·SEC Form 10-K, filed 2025-03-0471% match
“Our mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2671% match
“Our mission is to develop life-changing therapies for patients suffering from debilitating liver diseases.”In use 2021 – now·1 sighting·SEC Form 10-K, filed 2021-03-0971% match
“Our mission is to improve overall patient condition through innovative bio-immunotherapy with proven treatment protocols, to lower deaths associated with cancer and to reduce the cost of cancer treatment.”In use 2020 – now·1 sighting·SEC Form 10-K, filed 2020-03-2571% match
“Our mission is to accelerate transformative therapies to improve the lives of people living with cancer and other serious diseases.”In use 2017 – now·1 sighting·SEC Form 10-K, filed 2017-02-2370% match
“Our mission is to harness the evolutionary power of the human immune system to provide patients fighting cancer with safe, effective therapies.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1870% match
“Our mission is to design and deliver next generation immunotherapies for neurodegenerative and neuroinflammatory diseases.”In use 2026 – now·1 sighting·SEC Form 20-F, filed 2026-05-0170% match
“Our mission is to enable patients with these disorders to live fuller and healthier lives through the discovery and development of transformative precision peptide therapies.”In use 2025 – now·1 sighting·SEC Form 424B4, filed 2025-09-2570% match
“Our mission is to harness the power of the immune system to improve lives and eradicate cancer.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1270% match
“Our mission is to discover and develop effective biologic treatments applicable to a range of challenging, validated targets with high potential to help people with life-threatening conditions.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1970% match
“Our mission is to alleviate the most human suffering possible by developing active immunotherapy product candidates that improve the quality of care for chronic diseases and are accessible to all patients across the globe.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-2770% match
“Our mission is to develop and commercialize therapies with the potential to transform the lives of patients and their families living with rare diseases.”In use 2022 – now·1 sighting·SEC Form 10-K, filed 2022-03-0170% match
“Our mission is to develop new and effective immune-oncologic therapeutics.”In use 2015 – now·1 sighting·SEC Form 10-K, filed 2015-10-1470% match
“Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1970% match
“Our mission is to create transformative gene-based medicines for serious human diseases.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-1270% match
“Our mission is to bring life-changing therapeutics to people living with rare diseases.”In use 2025 – now·1 sighting·SEC Form 10-K, filed 2025-03-1269% match
“Our mission is to enable patients with these disorders to live fuller and healthier lives through the discovery and development of transformative therapies that overcome the key limitations of currently available treatments.”In use 2026 – now·1 sighting·SEC Form 424B4, filed 2026-08-1269% match
“Our mission is to overcome the limitations of cytokine therapies and checkpoint inhibitors, such as anti-CTLA-4, and make immunotherapies beyond anti-PD-1/PD-L1 treatments more accessible, efficacious and safe for patients with cancer.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-04-0169% match
“Our mission is to improve the lives of cancer patients by developing next-generation cancer therapies that are designed to maximize efficacy while minimizing the toxicity and side effects traditionally associated with cancer treatment.”In use 2020 – now·1 sighting·SEC Form 10-K, filed 2020-02-2169% match
“Our mission is to become a leading global, fully integrated biopharmaceutical company engaged in discovering, developing and commercializing both first- and best-in-class therapies to address global unmet medical needs primarily in hematological malignancies.”In use 2025 – now·1 sighting·SEC Form 424B4, filed 2025-01-2469% match
“Our purpose is to innovate to bring therapies to patients that significantly improve their lives.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-1369% match
“Our mission is to develop next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases.”In use 2025 – now·1 sighting·SEC Form S-1/A, filed 2025-11-2869% match
“Our mission is to develop novel therapies by utilizing our disease-agnostic platform to address areas of high unmet medical need, initially in cancer and neurologic diseases.”In use 2022 – now·1 sighting·SEC Form 10-K, filed 2022-03-1069% match
“Our mission is to improve the lives of cancer patients by developing therapies that are designed to maximize the effectiveness of RT while limiting the side effects of radiation in cancer treatment.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-03-1569% match
“Our mission is to leverage our unique insights into the chromatin regulatory system to pioneer the discovery, development and commercialization of a new class of therapies that transform the lives of patients suffering from a wide spectrum of diseases with high unmet need.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1169% match
“Our mission is to develop life-changing genetic medicines for people and their families impacted by devastating neurological diseases.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-2468% match
“Our mission is to develop innovative therapies that can transform patients' lives by addressing areas of high unmet medical need.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2368% match
Showing 1–50 of 50